# US 6,727,059 B1 · Method for controlling the fidelity and processivity of reverse transcriptase by incorporation and polymerization of nucleotide analogs accepted as substrates for the reverse transcription reaction without blocking its elongation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,059 B1
- Document ID: US6727059B1
- Status: Granted
- Kind: B1
- Application number: 09/926,492
- Filed: 2002-01-28
- Granted: 2004-04-27
- Earliest claimed: 2002-01-28
- Assignees: Centre National de la Recherche Scientifique (CNRS)
- Inventors: Valérie Derrien; Claude Reiss
- Web page: https://patentgrep.com/patent/US6727059B1

## CPC

- A61K 31/662: Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns the use of nucleotide analogues, defined as molecules acceptable as substrate of the reverse-transcription response and enabling the addition of at least one supplementary nucleotide to the polynucleotide chain during synthesis to affect and/or take over control of the fidelity and execution of the reverse transcription. The invention also concerns a pharmaceutical composition containing said nucleotide analogues.

## Claims

### Claim 1

A method of treating a condition involving reverse transcriptase in a subject, which comprises administering to the subject at least one nucleotide analog that is a substrate of reverse transcription, said nucleotide analog
a) has a 3′—H group located on the C3′ carbon of the 2′-deoxyribose, said 3′—OH group being capable of exchanging phosphodiester bonds with the chain being formed and the next nucleotide, and
b) does not terminate the reverse transcription.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the nucleotide analog makes it possible to control the fidelity of the reverse transcription.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein the nucleotide analog introduces a controlled mutation of the bases.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the nucleotide analog makes it possible to control the processivity of the reverse transcriptase.

### Claim 5 (depends on 2)

The method as claimed in claim 2, wherein said nucleotide analog:
(a) decreases, in a controlled manner, the fidelity of the reverse transcription, lowers, in a controlled manner, the processivity of the reverse transcriptase, decreases, in a controlled manner, the pause time of the reverse transcriptase, or a combination thereof;
(b) increases, in a controlled manner, the fidelity of the reverse transcription, increases, in a controlled manner, the processivity of the reverse transcriptase, extends, in a controlled manner, the pause time of the reverse transcriptase, or a combination thereof.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the condition is caused by a retroid virus.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein said retroid may infect humans, animals, or plants.

### Claim 8 (depends on 7)

The method as claimed in claim 7, wherein the retroid virus is a lentivirus, a RNA oncovirus, a spumavirus, or a hepadnavirus.

### Claim 9 (depends on 8)

The method as claimed in claim 8, wherein the lentivirus is a human immunodeficiency virus (HIV) or a human T-cell leukemia virus (HTLV).

### Claim 10 (depends on 8)

The method as claimed in claim 8, wherein the hepadnavirus is a hepatitis B virus (HBV).

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein the nucleotide analog introduces a mismatch.

### Claim 12 (depends on 11)

The method as claimed in claim 11, wherein the nucleotide analog pairs according to a pairing of the Wobble type.

### Claim 13 (depends on 11)

The method as claimed in claim 11, wherein the nucleotide analog pairs according to a pairing of the ANTI-SYN type.

### Claim 14 (depends on 11)

The method as claimed in claim 11, wherein the nucleotide analog pairs according to a pairing of the Hoogsteen type, the reverse Hoogsteen type, or both.

### Claim 15 (depends on 11)

The method as claimed in claim 11, wherein the nucleotide analog pairs according to a pairing of the reverse Watson-Crick type.

### Claim 16 (depends on 1)

The method of claim 1, wherein the nucleotide analog is an all natural modified nucleotide.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nucleotide analog is a modified nucleotide of prokaryotic or eukaryotic transfer RNAs (tRNAs).

### Claim 18 (depends on 17)

The method of claim 17, wherein the nucleotide analog is dUTP, dITP, C7dGTP, or C7dATP.

### Claim 19 (depends on 1)

The method of claim 1, wherein the nucleotide is exogenous to living cells.

### Claim 20 (depends on 19)

The method of claim 19, wherein the nucleotide analog comprises a modified base selected from the group consisting of 6H, 8H-3, 4-dihydropyrimido[4,5c][1,2]oxazin-7-one (P), and N6-methoxy-2,6-diaminopurine (K).

### Claim 21 (depends on 1)

The method of claim 1, wherein the nucleotide analog is in the triphosphate form or the deoxytriphosphate form.

### Claim 22 (depends on 1)

The method of claim 1, wherein the nucleotide analog further comprises a group which protects the functional groups.

### Claim 23 (depends on 1)

The method of claim 1, wherein the nucleotide analog is in the form of a bis(S-acyl-2-thioethyl) pronucleotide.

### Claim 24

A pharmaceutical composition comprising at least one nucleotide analog having a 3′-OH group located on the C3′carbon of the 2′-deoxyribose, said 3′-OH group being capable of exchanging phosphodiester bonds with the chain being formed and the next nucleotide, and does not terminate the reverse transcription reaction and a pharmaceutically acceptable vehicle.

### Claim 25 (depends on 24)

The pharmaceutical composition as claimed in claim 24, and further comprising at least one antiretroviral agent selected from the group consisting of nucleotide and non-nucleotide reverse transcriptase inhibitors and viral antiproteases.

### Claim 26 (depends on 25)

The pharmaceutical composition as claimed in claim 25, wherein the reverse transcriptase inhibitor is selected from the group consisting of 3′-azido-3′-deoxythymidine (AZT), 2′,3′-dideoxyinosine (ddI), 2′,3′-dideoxycytidine (ddC), (−)2′,3′-dideoxy-3′-thiacytidine (3TC), 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and (−)2′-deoxy-5-fluoro-3′-thiacytidine (FTC), TIBO (tetrahydroimidazo-(4,5,1-1, jk)(1,4)-benzodiapezin-2(1H)-one), HEPT (1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine), TSAO ([2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3′-spiro-5″- (4″-amino-1″,2″-oxathiol-2″,2″-dioxide), alpha-APA (alpha-anilinophenylacetamide), nevirapine, BAHP (bis(etheroaryl)piperazine), and phosphonoformic acid (PFA).

### Claim 27 (depends on 25)

The pharmaceutical composition as claimed in claim 25, wherein the viral antiprotease is indinavir or saquinavir.

### Claim 28 (depends on 3)

The method of claim 3, wherein the controlled mutation is a substitution mutation, a deletion mutation, or an insertion mutation.

### Claim 29 (depends on 9)

The method of claim 9, wherein the human immunodeficiency virus (HIV) is a human immunodeficiency virus type 1 (HIV-1).

### Claim 30 (depends on 16)

The method of claim 16, wherein the all natural modified nucleotide is modified nucleotide of prokaryotic or eukaryotic RNAs.
